ZLAB reports today with a notably charged short-selling backdrop — short interest has climbed roughly 33% over the past month, borrow availability has tightened sharply, and the CEO has been selling stock in size heading into the print.
The most concrete signal is in the lending market. Availability has dropped to around 41% — meaning for every two shares already borrowed, fewer than one remains available in the lending pool. That marks a meaningful tightening from levels above 100% just two weeks ago, and the 52-week low availability hit just 0.009%, so the direction of travel is clear. Cost to borrow jumped to 4.6%, more than eight times its mid-week reading of 0.53% a week prior, though the pattern is volatile day-to-day. Short interest itself has risen about 18% week-on-week to roughly 6.4 million shares, with the ORTEX short score holding in the high 60s — a level that ranks in the bottom 13th percentile of the broader universe on short positioning. That combination of rising shorts, tightening availability, and elevated borrow costs describes a market where demand to be short ZLAB is building faster than the lending pool can absorb it comfortably.
The bull-bear debate centres on whether Zai Lab's pipeline can justify the stock at current levels, against a backdrop of relentless target-price cuts. The analyst consensus remains constructive — buy-equivalent ratings dominate, and the mean target of around $33 implies roughly 87% upside from the $17.73 close. But that upside figure deserves scrutiny: Citigroup cut its target to $44 from $47 after the last earnings, and JP Morgan has trimmed twice this year, most recently to $32 from $39 in March. The direction of analyst travel is clearly lower. Bears point to deeply negative earnings and EBITDA, with the company still burning cash and the forward earnings yield firmly in negative territory. Bulls counter that 90-day EPS momentum has improved to the 72nd percentile and that the stock trades at a significant discount to even the most conservative targets.
Institutional activity heading into the print adds another layer. FMR (Fidelity) added nearly 1.9 million shares in its most recent filing, while TCG Crossover built a fresh position of nearly 5.9 million shares — a near-wholesale entry. Goldman Sachs, by contrast, cut its holding by over 900,000 shares. The CEO, Samantha Du, sold approximately 200,000 shares in May across multiple transactions at prices between $19 and $21, well above today's level of $17.73. The options market is striking in its own way: the put/call ratio runs at 3.7, roughly in line with its 20-day average, which itself is extraordinarily elevated — suggesting persistent structural demand for downside protection that has been a feature of the name for months rather than a fresh pre-earnings hedge.
Today's print will test whether Zai Lab's pipeline progress and commercial execution are sufficient to arrest the slide in analyst conviction and slow the accelerating build in short positions.
See the live data behind this article on ORTEX.
Open ZLAB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
